ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fischer, R
Right arrow Articles by Huber, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fischer, R
Right arrow Articles by Huber, R.
Eur Respir J 2000; 15: 123-127
Copyright © ERS Journals Ltd 2000


Clinical Trial

Theophylline improves acute mountain sickness

R Fischer, SM Lang, U Steiner, M Toepfer, H Hautmann, H Pongratz, and RM Huber

A randomized two-part study was conducted in order to determine the efficacy of theophylline in the treatment of acute mountain sickness during fast ascent to altitudes >2,500 m. Fourteen healthy male subjects participated in a randomized single-blind placebo-controlled crossover study carried out in a decompression chamber (simulated altitude 4,500 m). A second randomized single-blind, placebo-controlled study was conducted at a high-altitude research laboratory (3,454 m) and included 21 healthy male subjects. The study medication was either 375 mg oral slow-release theophylline (250 mg if <70 kg) or a matched placebo tablet taken twice daily. The acute mountain sickness score (AMSS) was assessed three times a day, beginning 18 h prior to altitude exposure and continuing for 18 h after altitude exposure. In addition, measurements of respiratory frequency, pulse rate, oxygen saturation and arterial blood gas levels were performed. Acute mountain sickness was significantly reduced by theophylline during the decompression chamber study (mean+/-SD 1.2+/-0.9) with placebo versus 3.6+/-0.8 with theophylline; p=0.03). During the high-altitude study, subjects with theophylline showed a significantly lower AMSS on arrival and after 18 h at altitude (0.6 versus 2.3, p=0.03). Oxygenation was improved in both parts of the study. In conclusion, oral slow-release theophylline improves acute mountain sickness.


This article has been cited by other articles:


Home page
Eur Respir JHome page
R. Fischer, S.M. Lang, M. Leitl, M. Thiere, U. Steiner, and R.M. Huber
Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude
Eur. Respir. J., January 1, 2004; 23(1): 47 - 52.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
A. Ellsworth
Pharmacotherapy for Altitude-Related Illness
Journal of Pharmacy Practice, February 1, 2003; 16(1): 68 - 75.
[Abstract] [PDF]


Home page
Eur Respir JHome page
R. Fischer, S.M. Lang, and R.M. Huber
Does theophylline really improve acute mountain sickness?
Eur. Respir. J., May 1, 2001; 17(5): 1053 - 1053.
[Full Text] [PDF]


Home page
Eur Respir JHome page
G. Roggla, W. Domej, and M. Roggla
Does theophylline really improve acute mountain sickness?
Eur. Respir. J., March 1, 2001; 17(3): 575 - 575.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the European Respiratory Society.